Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
🌎 Global
Global
United States
Australia
United Kingdom
Canada
India
China
Argentina
Austria
Bahrain
Bangladesh
Belgium
Bermuda
Botswana
Brazil
Bulgaria
Chile
Colombia
Croatia
Cyprus
Czech Republic
Denmark
Egypt
Estonia
Finland
France
Germany
Ghana
Greece
Hong Kong
Hungary
Iceland
Indonesia
Ireland
Israel
Italy
Ivory Coast
Jamaica
Japan
Jordan
Kenya
Kuwait
Latvia
Lithuania
Luxembourg
Malawi
Malaysia
Malta
Mauritius
Mexico
Morocco
Namibia
Netherlands
New Zealand
Nigeria
Norway
Oman
Pakistan
Palestinian Authority
Peru
Philippines
Poland
Portugal
Qatar
Romania
Russia
Saudi Arabia
Serbia
Singapore
Slovakia
Slovenia
South Africa
South Korea
Spain
Sri Lanka
Sweden
Switzerland
Taiwan
Tanzania
Thailand
Trinidad & Tobago
Tunisia
Turkey
Uganda
Ukraine
United Arab Emirates
Venezuela
Vietnam
Zambia
Zimbabwe
Create a narrative
Global Community
Our community narratives are driven by numbers and valuation.
Create a narrative
Community Investing Ideas
Global Weekly Picks
GXAI
Gaxos.ai
Sponsored
content by Gaxos.ai
JO
Jolt_Communications
Community Contributor
Gaxos.ai: Early-Stage AI Innovator in Gaming & Health
Key Takeaways Dual AI focus – Gaxos.ai builds AI-powered tools for game developers (via Unity integrations) and AI-driven health services under its RNK Health brand. First signs of commercial traction – After years of development, the company reported ~$194k in H1 2025 revenue, mainly from wellness pilot programs.
View narrative
US$2.21
FV
24.9% overvalued
intrinsic discount
119.00%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
1
users have commented on this narrative
20
users have followed this narrative
New
narrative
Microsoft
PI
PicaCoder
Community Contributor
After the AI Party: A Sobering Look at Microsoft's Future
The world has been captivated by the artificial intelligence boom, and no company has ridden the wave of investor enthusiasm quite like Microsoft. Buoyed by its strategic partnership with OpenAI and the integration of AI across its product ecosystem, the company's valuation has soared to unprecedented heights.
View narrative
US$500.00
FV
0.8% overvalued
intrinsic discount
6.75%
Revenue growth p.a.
Set Fair Value
18
users have liked this narrative
9
users have commented on this narrative
24
users have followed this narrative
10 days ago
author updated this narrative
Amazon.com
ZW
Zwfis
Community Contributor
Amazon's Future Rises as Stock Price Falls: A Long-Term Investment Vision
Amazon is a stock I am very interested in right now especially with the recent price drops that it has been experiencing since its 2Q25 results. A summary of Amazon as stated by Fiscal.ai: "Amazon.com, Inc.
View narrative
US$234.75
FV
5.5% undervalued
intrinsic discount
13.60%
Revenue growth p.a.
Set Fair Value
18
users have liked this narrative
7
users have commented on this narrative
22
users have followed this narrative
New
narrative
Verve Group
TI
TibiT
Community Contributor
Verve Group: A Tale of Three Futures
Verve Group stands at a critical juncture. After a history of explosive growth, the company has been hit by significant operational headwinds, primarily the difficult and costly migration to a unified technology platform and unfavorable currency exchange rates.
View narrative
€4.02
FV
45.5% undervalued
intrinsic discount
8.50%
Revenue growth p.a.
Set Fair Value
3
users have liked this narrative
0
users have commented on this narrative
15
users have followed this narrative
Updated
narrative
All companies
Popular
Undervalued
Overvalued
Load previous narratives
Ypsomed Holding
AN
AnalystHighTarget
Consensus Narrative from 8 Analysts
Connected Self-Injection Devices Will Redefine Chronic Care Globally
Key Takeaways Sharpened focus on high-margin self-injection systems and digital health devices is expected to sustainably improve margins and accelerate growth. Unique product portfolio and strong pharma partnerships position Ypsomed to benefit from industry outsourcing trends and surging demand for home-based care solutions.
View narrative
CHF 495.00
FV
18.4% undervalued
intrinsic discount
11.94%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
1 day ago
author updated this narrative
Zealand Pharma
AN
AnalystConsensusTarget
Consensus Narrative from 15 Analysts
Clinical Catalysts And Roche Alliance Will Advance Obesity Amid Risks
Key Takeaways Major data from obesity drug trials and new industry alliances position the company for expanded future revenues, lowered commercialization risks, and greater global market access. Strong financial reserves enable self-funded innovation and product launches, with pipeline diversification aligning well with emerging trends in obesity treatment.
View narrative
DKK 835.47
FV
50.7% undervalued
intrinsic discount
-36.66%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
18
users have followed this narrative
New
narrative
Hexagon
AN
AnalystLowTarget
Consensus Narrative from 18 Analysts
Intensified Regulation And Deglobalization Will Curtail Automation Prospects
Key Takeaways Rising regulatory scrutiny, competitive pressure, and hardware commoditization are expected to constrain growth and erode margins in Hexagon's core software and geospatial businesses. Ongoing dependence on acquisitions and increasing R&D investment risks undermine free cash flow and threaten future earnings quality.
View narrative
SEK 88.94
FV
20.0% overvalued
intrinsic discount
3.67%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
1 day ago
author updated this narrative
Danske Bank
AN
AnalystLowTarget
Consensus Narrative from 15 Analysts
Digital Shift And Rising Regulatory Costs Will Squeeze European Margins
Key Takeaways Disruptive digital competitors and new technologies threaten to erode Danske Bank's core revenues and diminish its long-term market position. Mounting regulatory, legal, and reputational challenges are likely to drive up costs and limit both profitability and growth prospects.
View narrative
DKK 192.49
FV
43.2% overvalued
intrinsic discount
-1.90%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
1 day ago
author updated this narrative
Vodafone Idea
AN
AnalystHighTarget
Consensus Narrative from 22 Analysts
India's 5G Adoption And Digital Expansion Will Fuel Momentum
Key Takeaways Rapid 4G/5G expansion and digital ecosystem integration are driving subscriber growth, higher margins, and non-traditional revenue streams. Strategic rural broadband, IoT, and enterprise solutions position Vodafone Idea for resilient, long-term growth and market leadership.
View narrative
₹12.39
FV
47.2% undervalued
intrinsic discount
15.56%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
2
users have followed this narrative
1 day ago
author updated this narrative
Nokia Oyj
AN
AnalystLowTarget
Consensus Narrative from 21 Analysts
US, Europe And China Tensions Will Compress Network Margins
Key Takeaways Persistent geopolitical and trade tensions, talent competition, and industry commoditization threaten Nokia's revenue growth, margin stability, and market access. Rapid tech disruption and uncertain demand for next-gen networks force costly reinvestment, risking underutilized capacity and weaker long-term profitability.
View narrative
€3.03
FV
19.6% overvalued
intrinsic discount
2.02%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
1 day ago
author updated this narrative
Bayer
AN
AnalystLowTarget
Consensus Narrative from 19 Analysts
Crop Science And Pharmaceuticals Will Suffer Under Mounting Liabilities
Key Takeaways Persistent legal, regulatory, and debt challenges are constraining Bayer's cash flow, margins, and financial flexibility, threatening both investment capacity and shareholder returns. Shifting market preferences and regulatory environments, alongside rising competition, are impeding revenue growth and eroding the long-term sustainability of core business segments.
View narrative
€23.00
FV
22.3% overvalued
intrinsic discount
-0.10%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
1 day ago
author updated this narrative
SPIE
AN
AnalystHighTarget
Consensus Narrative from 10 Analysts
Accelerated Energy Transition And Digitalization Will Transform Infrastructure
Key Takeaways SPIE's leadership in energy transition and specialty services, combined with skilled labor shortages, positions it for sustained margin expansion, pricing power, and exceptional profitability. Its rapid integration of high-value bolt-ons and focus on recurring outsourcing contracts underpin resilient cash flows, compounding growth, and the potential for superior shareholder returns.
View narrative
€62.00
FV
15.9% undervalued
intrinsic discount
7.37%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
1 day ago
author updated this narrative
Imperial Brands
AN
AnalystLowTarget
Consensus Narrative from 12 Analysts
Rising Regulation And Illicit Trade Will Erode Tobacco Revenues
Key Takeaways Long-term decline in tobacco and regulatory pressures will steadily erode core revenues and compress margins, particularly in mature markets. Heavy reliance on pricing power and insufficient innovation in next-generation products threaten future growth and risk falling behind more adaptive competitors.
View narrative
UK£24.21
FV
28.9% overvalued
intrinsic discount
-23.74%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
1 day ago
author updated this narrative
Value any company in seconds
Popular companies